Search results
Showing 31 to 36 of 36 results for alzheimer's disease
intravenous iron preparations in children with anaemia of chronic kidney disease (CKD), including safety, dosing and efficacy outcomes.
Second consultation launched on NHS funding for Alzheimer's treatments
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab.
New Alzheimer's treatment donanemab does not currently demonstrate value for the NHS says NICE
More evidence is needed on the clinical and cost-effectiveness of donanemab, a new treatment for mild Alzheimer’s disease.
Benefits of new Alzheimer's treatment lecanemab are too small to justify the cost to the NHS
Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, with the cost of treatment.
Working at the forefront of neurodegenerative disease research
Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.
NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.